From Mutation to Metabolism: Toxins, Mitochondria, and Integrative Orthomolecular Cancer Therapy (IOCT) — Implications for ASCVD and T2DM

Conventional oncology remains mutation-centric despite modest survival gains and substantial toxicity. Converging evidence indicates that environmental and dietary toxins, together with micronutrient insufficiency, act upstream to damage mitochondria—precipitating redox collapse, impaired oxidative phosphorylation, metabolic inflexibility, genomic instability, and therapy resistance. These lesions not only initiate and sustain malignancy but also underpin a broader chronic-disease continuum that includes atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM).Building on prior root-cause analyses, we introduce the Triple-Principle Intervention Model (TPIM)—Safety first, Effectiveness via titration-to-target, and Affordability—as a conservative clinical filter for Integrative Orthomolecular Medicine. We then operationalize Integrative Orthomolecular Cancer Therapy (IOCT) through a systems-based program combining restricted ketogenic nutrition and fasting; high-dose intravenous vitamin C; targeted micronutrient repletion (e.g., niacin/NAD⁺, D3/K2, Mg, omega-3); mitochondrial redox modulation (e.g., PBMT/“Red–Blue” with methylene blue); immune-inflammation regulation; bioidentical hormone optimization; and circadian/lifestyle realignment.To evaluate such multi-modal, adaptive care, we propose the Triple-Principle Adaptive RCT (TP-ARC)—a next-generation clinical trial framework that prioritizes clinical outcomes over isolated pharmacologic effects. Unlike conventional drug-centric RCTs designed to test single agents under rigid inclusion criteria, TP-ARC assesses the whole-person therapeutic program and its impact on quality of life, functional capacity, and survival. Biomarker titration serves as a secondary, supportive tool rather than the primary endpoint. By adapting interventions to fit each patient—rather than forcing patients to fit protocols—TP-ARC bridges real-world practice and research, embodying a pragmatic, ethical, and patient-centered evolution of clinical science.This mitochondrial-metabolism-focused integrative framework reframes cancer as a preventable and modifiable systems disorder, enabling ethical and economical bedside translation while providing mechanistic continuity with ASCVD and T2DM to guide future cross-disciplinary trials.